International Randomized Multicenter Phase III Study in Patients with Relapsing Remitting Multiple Sclerosis Comparing Over a Treatment Period of 104 Weeks: BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose

  • Berger, Joseph (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date3/15/046/30/08